Salvatore Lo Fermo

Catania, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Incidence of Multiple Sclerosis in the City of Catania: A 50-Year Observational Population-Based Study.

Incidence of Multiple Sclerosis in the City of Catania: A 50-Year Observational Population-Based Study.

Journal: Neuroepidemiology

Published: March 26, 2026

Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.

Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: February 23, 2026

Trace metal signatures in cerebrospinal fluid (CSF): Insights from an amyotrophic lateral sclerosis (ALS) hotspot on Mount Etna (Sicily, Italy).

Trace metal signatures in cerebrospinal fluid (CSF): Insights from an amyotrophic lateral sclerosis (ALS) hotspot on Mount Etna (Sicily, Italy).

Journal: Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

Published: September 30, 2025

Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).

Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).

Journal: Journal of neurology

Published: July 16, 2025

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients.

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients.

Journal: Therapeutic advances in neurological disorders

Published: May 14, 2025

Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients.

Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: April 17, 2025

Incidence of late onset multiple sclerosis in Italy: a population-based study.

Incidence of late onset multiple sclerosis in Italy: a population-based study.

Journal: Scientific reports

Published: October 11, 2024

In vivo Effects of Disease-modifying Therapies on Immunological Subsets in Patients with Relapsing-Remitting Multiple Sclerosis.

In vivo Effects of Disease-modifying Therapies on Immunological Subsets in Patients with Relapsing-Remitting Multiple Sclerosis.

Journal: Current neuropharmacology

Published: September 15, 2024

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 04, 2024

Beyond the bowel: Wernicke's encephalopathy as a neurological complication of Crohn's disease: A case report.

Beyond the bowel: Wernicke's encephalopathy as a neurological complication of Crohn's disease: A case report.

Journal: Radiology case reports

Published: March 10, 2024

Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.

Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.

Journal: Multiple sclerosis and related disorders

Published: October 08, 2023

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: July 11, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026